eFFECTOR Therapeutics, Inc. (EFTR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -33.84 Million USD | -4.45% |
| 2022 | -32.4 Million USD | -1.59% |
| 2021 | -31.89 Million USD | -301.64% |
| 2020 | 15.81 Million USD | 155.3% |
| 2019 | -28.6 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -8.39 Million USD | 2.34% |
| 2023 Q3 | -8.3 Million USD | -5.7% |
| 2023 FY | -33.84 Million USD | -4.45% |
| 2023 Q4 | -8.59 Million USD | -3.54% |
| 2023 Q2 | -7.85 Million USD | 15.76% |
| 2023 Q1 | -9.32 Million USD | -6.9% |
| 2022 Q4 | -8.72 Million USD | 5.71% |
| 2022 Q1 | -6.54 Million USD | -132.69% |
| 2022 Q3 | -9.25 Million USD | -17.38% |
| 2022 FY | -32.4 Million USD | -1.59% |
| 2022 Q2 | -7.88 Million USD | -20.36% |
| 2021 FY | -31.89 Million USD | -301.64% |
| 2021 Q3 | -8.71 Million USD | -72.76% |
| 2021 Q2 | -5.04 Million USD | 12.08% |
| 2021 Q1 | -5.73 Million USD | -2.1% |
| 2021 Q4 | 20.02 Million USD | 329.85% |
| 2020 Q3 | -7.26 Million USD | -179.84% |
| 2020 Q4 | -5.61 Million USD | 22.7% |
| 2020 FY | 15.81 Million USD | 155.3% |
| 2020 Q1 | 19.6 Million USD | 0.0% |
| 2020 Q2 | 9.1 Million USD | -53.56% |
| 2019 FY | -28.6 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -6769.87% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -255.579% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -12.84% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 49.594% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -113.621% |
| Better Therapeutics, Inc. | -38.26 Million USD | 11.547% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 19.561% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -182.74% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 1.671% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 68.798% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -1580.185% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 0.465% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 27.916% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -2375.088% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -69.735% |
| Molecular Templates, Inc. | -10.46 Million USD | -223.371% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -140.867% |
| NexImmune, Inc. | -29.19 Million USD | -15.934% |
| Orgenesis Inc. | -53.63 Million USD | 36.901% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 34.02% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -43280.289% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -109.622% |
| Scopus BioPharma Inc. | -11.71 Million USD | -188.898% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 93.289% |
| Statera Biopharma, Inc. | -98.34 Million USD | 65.586% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -390.635% |
| Trevena, Inc. | -35.28 Million USD | 4.092% |
| Vaxxinity, Inc. | -58.28 Million USD | 41.934% |
| Vaccinex, Inc. | -22.88 Million USD | -47.887% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -3132.542% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 33.237% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -365.977% |